The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …

Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Despite therapeutic advances against SARS-CoV-2, including multiple vaccines, oral
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …

Background The COVID-19 pandemic heightened risks for individuals with hematological
malignancies due to compromised immune systems, leading to more severe outcomes and …

COVID-19 still represents a major issue for patients with lymphoid malignancies, especially
those on therapy, because of immune suppression and suboptimal responses to …

Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in
immunocompetent patients with COVID-19, but data on efficacy in patients with …

The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in
immunosuppressed patients such as hematological patients has been little explored. A …

The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current
or past history of cancer facing disparate consequences at every stage of the cancer …

Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …